Soligenix Inc
SNGX
查看詳細走勢圖
1.380USD
+0.150+12.20%
收盤 12/19, 16:00（美東）報價延遲15分鐘
13.61M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+12.20%
5天
-16.36%
1月
+8.66%
6月
-18.82%
今年開始到現在
-48.79%
1年
-53.22%
查看詳細走勢圖
TradingKey Soligenix Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
Soligenix Inc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名189/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價17.50。中期看，股價處於下降通道。近一個月，市場表現一般，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Soligenix Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
1
分析師
買入
評級
17.500
目標均價
+1007.59%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Soligenix Inc亮點
亮點風險
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
業績增長期
公司處於發展階段，最新年度總收入119.37K美元
估值高估
公司最新PE估值-0.40，處於3年歷史高位
機構減倉
最新機構持股242.17K股，環比減少30.95%
先鋒集團持倉
明星投資者先鋒集團持倉，最新持倉52.52K股
Soligenix Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Soligenix Inc簡介
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
公司代碼SNGX
公司Soligenix Inc
CEOSchaber (Christopher J)
網址https://www.soligenix.com/
常見問題
Soligenix Inc(SNGX)的當前股價是多少？
Soligenix Inc(SNGX)的當前股價是 1.380。
Soligenix Inc 的股票代碼是什麼？
Soligenix Inc的股票代碼是SNGX。
Soligenix Inc股票的52週最高點是多少？
Soligenix Inc股票的52週最高點是6.230。
Soligenix Inc股票的52週最低點是多少？
Soligenix Inc股票的52週最低點是1.090。
Soligenix Inc的市值是多少？
Soligenix Inc的市值是13.61M。
Soligenix Inc的淨利潤是多少？
Soligenix Inc的淨利潤為-8.27M。
現在Soligenix Inc(SNGX)的股票是買入、持有還是賣出？
根據分析師評級，Soligenix Inc(SNGX)的總體評級為買入，目標價格為17.500。
Soligenix Inc(SNGX)股票的每股收益（EPS TTM）是多少
Soligenix Inc(SNGX)股票的每股收益（EPS TTM）是-3.444。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
